Amsterdam-based myTomorrows raises €10 million to improve access to drugs in development for physicians and patients

0
230
myTomorrows

Founded to facilitate access to drugs in development for physicians and their patients, myTomorrows today announced a €10 million growth funding round, co-led by EQT Ventures and Octopus Ventures. Existing investors Balderton Capital and Sofinnova Partners also participated in this round. Former GlaxoSmithKline Chief Medical Officer James Shannon has been appointed Chairman of the supervisory board.

Founded in 2012, and currently active in 17 countries, myTomorrows aims to change the way physicians and their patients access investigational drugs, rendering potentially life-saving drugs out of reach. By applying latest technologies, myTomorrows has built a platform for doctors and patients seeking information on and access to investigational drugs, and drugs that have been approved by regulators in other countries. On the other side, myTomorrows offers drug developers a seamless turn-key solution for global early access programs to make their drugs accessible to those suffering from life threatening or debilitating diseases whilst gathering data.

myTomorrows will use the fresh capital to further accelerate investments in technologies and talent in order to continue to unburden regulators, physicians and drug developers from the complex processes of providing access to investigational drugs for patients facing unmet medical needs.

Founder CEO Ronald Brus MD stated: “EQT Ventures has unparalleled marketplace experience – and in particular, we’re looking forward to working with Kees Koolen, who has incredible experience in disrupting existing markets through technology, both during his time running Booking.com and as an advisor to Uber. Plus the team at Octopus will help us in scaling the business, just as they did so successfully with Graze, Zoopla and Secret Escapes. With James Shannon taking the Chairman role, and the necessary funding now in place, myTomorrows is ready to accelerate the development of our technologies, the scaling of our platform to the US and Asia, as well as further growth in EU, LatAm & ME”.

Kees Koolen, Founding Partner, EQT Ventures, said: “myTomorrows has the opportunity to genuinely disrupt an industry, and solve a problem which could change many people’s lives. The team has incredible drive and deep expertise across medicine, biotech and technology. In an era where information asymmetry has been removed by the internet, myTomorrows has created a digital marketplace connecting physicians with drug developers under the watchful eye of local regulators, in order to facilitate access to drugs that might otherwise be out of reach for patients who have run out of other treatment options.”